跳至主要内容
临床试验/NCT02016976
NCT02016976Unknown不适用

Effect of Local Anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) Cream and Reduction in Dose, Pain and Intravenous Analgesic During Permanent Pacemaker Implantation

Hillel Yaffe Medical Center1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2014年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
40
试验地点
1
主要终点
Pain reduction

研究概览

简要总结

The investigators believe that the local anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) cream will lessen pain and reduce the need for anesthesia and analgesia, when implanting a permanent pacemaker.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients undergoing pacemaker implantation

排除标准

  • Dementia Patients
  • Psychiatric Patients
  • Unconscious Patients
  • Patients with sensitivity to EMLA

研究组 & 干预措施

EMLA analgesic cream

Active Comparator

Patients who have had EMLA analgesic cream applied to area before pacemaker implantation

干预措施: EMLA Analgesic Cream (Drug)

Routine treatment

Active Comparator

Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation

干预措施: Dormicum 2.5 mg and Pethidine 25 mg (Drug)

结局指标

主要结局

Pain reduction

时间窗: One hour

EMLA anesthetic cream will be applied to area where pacemaker is to be implanted. Pain reduction will be measured using the visual analog scale (VAS) at three intervals.

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验